554 related articles for article (PubMed ID: 28737986)
1. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
[TBL] [Abstract][Full Text] [Related]
2. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis.
Earla JR; Li J; Hutton GJ; Bentley JP; Aparasu RR
Mult Scler Relat Disord; 2024 May; 85():105539. PubMed ID: 38574721
[TBL] [Abstract][Full Text] [Related]
3. Teriflunomide for multiple sclerosis.
He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Reder AT; Centonze D; Naylor ML; Nagpal A; Rajbhandari R; Altincatal A; Kim M; Berdofe A; Radhakrishnan M; Jung E; Sandrock AW; Smirnakis K; Popescu C; de Moor C
CNS Drugs; 2021 Mar; 35(3):317-330. PubMed ID: 33743151
[TBL] [Abstract][Full Text] [Related]
5. Incidence of type 2 diabetes, cardiovascular disease and chronic kidney disease in patients with multiple sclerosis initiating disease-modifying therapies: Retrospective cohort study using a frequentist model averaging statistical framework.
Brnabic AJM; Curtis SE; Johnston JA; Lo A; Zagar AJ; Lipkovich I; Kadziola Z; Murray MH; Ryan T
PLoS One; 2024; 19(3):e0300708. PubMed ID: 38517926
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Van Der Walt A; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Blanco Morgado Y; Spitaleri D; van Pesch V; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H
Mult Scler; 2023 Feb; 29(2):221-235. PubMed ID: 36433775
[TBL] [Abstract][Full Text] [Related]
7. Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis.
Earla JR; Li J; Hutton GJ; Johnson ML; Aparasu RR
Pharmacotherapy; 2023 Jun; 43(6):473-484. PubMed ID: 37157135
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis.
Hua LH; Hersh CM; Morten P; Kusel J; Lin F; Cave J; Varga S; Herrera V; Ko JJ
J Manag Care Spec Pharm; 2019 Apr; 25(4):490-498. PubMed ID: 30917079
[TBL] [Abstract][Full Text] [Related]
9. Adherence and persistence to self-administered disease-modifying therapies in patients with multiple sclerosis: A multisite analysis.
Zuckerman AD; DeClercq J; Simonson D; Zagel AL; Turco E; Banks A; Wawrzyniak J; Rightmier E; Blevins A; Choi L
Mult Scler Relat Disord; 2023 Jul; 75():104738. PubMed ID: 37182475
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis.
Hou J; Kim N; Cai T; Dahal K; Weiner H; Chitnis T; Cai T; Xia Z
JAMA Netw Open; 2021 Nov; 4(11):e2134627. PubMed ID: 34783826
[TBL] [Abstract][Full Text] [Related]
12. Prediction of disease activity and treatment failure in relapsing-remitting MS patients initiating daily oral DMTs.
Pappolla A; Auger C; Sao-Aviles A; Tur C; Rodriguez-Barranco M; Cobo-Calvo Á; Mongay-Ochoa N; Rodríguez-Acevedo B; Zabalza A; Midaglia L; Carbonell-Mirabent P; Carvajal R; Castilló-Justribó J; Braga N; Bollo L; Vidal-Jordana A; Arrambide G; Nos C; Salerno A; Galán I; Comabella M; Sastre-Garriga J; Tintoré M; Rovira A; Montalban X; Río J
Mult Scler; 2024 Jun; 30(7):820-832. PubMed ID: 38551315
[TBL] [Abstract][Full Text] [Related]
13. Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis.
Nicholas JA; Edwards NC; Edwards RA; Dellarole A; Grosso M; Phillips AL
BMC Neurol; 2020 Jul; 20(1):281. PubMed ID: 32664928
[TBL] [Abstract][Full Text] [Related]
14. Medication adherence and health outcomes in persons with multiple sclerosis treated with dimethyl fumarate.
Jožef M; Locatelli I; Brecl Jakob G; Rot U; Kos M
Mult Scler Relat Disord; 2023 Apr; 72():104615. PubMed ID: 36933300
[TBL] [Abstract][Full Text] [Related]
15. Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.
Zhu C; Kalincik T; Horakova D; Zhou Z; Buzzard K; Skibina O; Alroughani R; Izquierdo G; Eichau S; Kuhle J; Patti F; Grand'Maison F; Hodgkinson S; Grammond P; Lechner-Scott J; Butler E; Prat A; Girard M; Duquette P; Macdonell RAL; Weinstock-Guttman B; Ozakbas S; Slee M; Sa MJ; Van Pesch V; Barnett M; Van Wijmeersch B; Gerlach O; Prevost J; Terzi M; Boz C; Laureys G; Van Hijfte L; Kermode AG; Garber J; Yamout B; Khoury SJ; Merlo D; Monif M; Jokubaitis V; van der Walt A; Butzkueven H;
JAMA Neurol; 2023 Jul; 80(7):739-748. PubMed ID: 37273217
[TBL] [Abstract][Full Text] [Related]
16. Adherence to Disease-Modifying Therapies for Multiple Sclerosis.
Higuera L; Carlin CS; Anderson S
J Manag Care Spec Pharm; 2016 Dec; 22(12):1394-1401. PubMed ID: 27882830
[TBL] [Abstract][Full Text] [Related]
17. Effect of smoking on disease activity in multiple sclerosis patients treated with dimethyl fumarate or fingolimod.
Tanaka E; Watanabe M; Fukumoto S; Masaki K; Yamasaki R; Matsushita T; Isobe N
Mult Scler Relat Disord; 2023 Feb; 70():104513. PubMed ID: 36689892
[TBL] [Abstract][Full Text] [Related]
18. A comparison of clinical, utilization, and cost outcomes between oral treatments for multiple sclerosis.
Racsa P; Kiss C; Stevens L; Dixon SW; Ellis JJ
J Manag Care Spec Pharm; 2024 Feb; 30(2):129-140. PubMed ID: 38308623
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
Diouf I; Malpas CB; Sharmin S; Roos I; Horakova D; Kubala Havrdova E; Patti F; Shaygannejad V; Ozakbas S; Eichau S; Onofrj M; Lugaresi A; Alroughani R; Prat A; Duquette P; Terzi M; Boz C; Grand'Maison F; Sola P; Ferraro D; Grammond P; Yamout B; Altintas A; Gerlach O; Lechner-Scott J; Bergamaschi R; Karabudak R; Iuliano G; McGuigan C; Cartechini E; Hughes S; Sa MJ; Solaro C; Kappos L; Hodgkinson S; Slee M; Granella F; de Gans K; McCombe PA; Ampapa R; van der Walt A; Butzkueven H; Sánchez-Menoyo JL; Vucic S; Laureys G; Sidhom Y; Gouider R; Castillo-Trivino T; Gray O; Aguera-Morales E; Al-Asmi A; Shaw C; Al-Harbi TM; Csepany T; Sempere AP; Treviño Frenk I; Stuart EA; Kalincik T
J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):1004-1011. PubMed ID: 37414534
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study.
Brownlee WJ; Haghikia A; Hayward B; Waser N; Kayaniyil S; Khan Z; Duncan J; Millar S; Harty GT
Mult Scler Relat Disord; 2023 Aug; 76():104791. PubMed ID: 37343465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
